TMCnet14m
NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights
The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.
pharmaphorum21h
11 blockbuster drugs to look out for in 2025
2) Novo Nordisk's CagriSema (cagrilintide and semaglutide), a fixed-dose combination of an amylin analogue and GLP-1 agonist for obesity and type 2 diabetes and successor to the company's big ...